article thumbnail

Oncotarget: A novel format for recombinant antibody-interleukin-2 fusion proteins

Scienmag

Oncotarget recently published a novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe four novel formats for the L19-IL2 fusion Credit: Correspondence to – Dario Neri – dario.neri@pharma.ethz.ch

article thumbnail

Purolite and Repligen to commercially launch novel CH1 affinity resin

BioPharma Reporter

Ion exchange resin manufacturer Purolite and bioprocessing technology firm Repligen have announced the commercial launch of Praesto CH1, an affinity resin designed to purify specialized mAbs such as bispecifics and recombinant antibody fragments.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Salk team reveals never-before-seen antibody binding, informing liver cancer, antibody design

Scienmag

Multi-institute collaboration uses X-ray crystallography and recombinant antibodies to uncover workings of an elusive molecule central to human health Credit: Salk Institute LA JOLLA–(February 17, 2021) In structural biology, some molecules are so unusual they can only be captured with a unique set of tools.

article thumbnail

New anti-evolocumab antibodies could aid drug development

Drug Discovery World

Bio-Rad Laboratories has introduced a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels. .

article thumbnail

Grifols’ Innovation Strategy in the Plasma Medicine Space

XTalks

Our pipeline, for example, includes a new class of recombinant antibodies. Right now, they are doing what is probably the most advanced work in the field of polyclonal recombinant antibody therapies. The science is brilliant.

Medicine 111
article thumbnail

Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors

The Pharma Data

From this, BT-001 is engineered to encode both a highly differentiated Treg depleting anti-CTLA4 antibody and the human GM-CSF cytokine. The recombinant antibody recognizing human CTLA4 was generated by BioInvent’s proprietary n-CoDeR®/F.I.R.S.T

Trials 40
article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

The luncheon presentations include: Matthias Hillenbrand, PhD, Head, Infectious Disease Research & Biosafety Officer, Memo Therapeutics, on: ‘Best in class antiviral antibodies from cognate recombinant antibody repertoires of human donors’.